We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pediatric Group Opposes Merz Bid for Cuvposa Pediatric Exclusivity
Pediatric Group Opposes Merz Bid for Cuvposa Pediatric Exclusivity
Six months of additional pediatric exclusivity should be granted only to products that add a children-specific indication, and only if the drug sponsor receives a specific written request from the FDA for studies to support the label expansion, according to the American Academy of Pediatrics.